Mark Albright, MD
Nephrology · Colorado Springs, CONPI 1104824259
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AstraZeneca at 24.3% of the total. 2025 is the largest year on record at $1,311, 3.7 times the $351 reported in 2019.
Across 220 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$756
- Otsuka America Pharmaceutical, Inc.$358
- Novo Nordisk$224
- Calliditas Therapeutics US Inc.$199
- Bayer$193
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,59899%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 53 | $1,125 |
| Amgen(2 entities) | 36 | $756 |
| Otsuka America Pharmaceutical, Inc. | 17 | $358 |
| Novo Nordisk | 8 | $224 |
| Calliditas Therapeutics US Inc. | 9 | $199 |
| Bayer | 10 | $193 |
| Travere Therapeutics, Inc. | 11 | $181 |
| Novartis | 8 | $161 |
| Aurinia Pharma U.S., Inc. | 7 | $157 |
| GSK | 8 | $156 |
| Daiichi Sankyo Inc. | 7 | $128 |
| Boehringer Ingelheim | 5 | $115 |
| Fresenius USA Marketing, Inc. | 6 | $112 |
| Mallinckrodt Hospital Products Inc. | 5 | $109 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $82 |
| Ardelyx, Inc. | 3 | $82 |
| Vifor Pharma, Inc. | 3 | $82 |
| ANI Pharmaceuticals, Inc. | 3 | $63 |
| Apellis Pharmaceuticals, Inc. | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $40 |
| OPKO Pharmaceuticals, LLC | 2 | $36 |
| Sanofi | 1 | $26 |
| Nxstage Medical, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Outset Medical Inc | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Akebia Therapeutics Inc | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Amicus Therapeutics, Inc. | 1 | $14 |
How this compares
$4,627 in reported general payments places this provider in the 85th percentile of 152 nephrology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $12,628 |
| Sevelamer Carbonate | 27 | $4,884 |
| Calcium Acetate | 19 | $1,479 |
| Calcitriol | 51 | $1,021 |
| Amlodipine Besylate | 98 | $784 |
| Carvedilol | 55 | $720 |
| Losartan Potassium | 50 | $590 |
| Cinacalcet Hcl | 11 | $538 |
| Spironolactone | 43 | $464 |
| Omeprazole | 23 | $446 |
| Hydralazine Hcl | 25 | $439 |
| Bumetanide | 11 | $420 |
| Lisinopril | 53 | $365 |
| Ondansetron Hcl | 12 | $258 |
| Metoprolol Succinate | 15 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $115 | $12,62812 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $63 | $15612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 152 nephrology providers in Colorado.
Other nephrology in Colorado Springs
- Jesse FlaxenburgColorado Springs$6K
- Melinda HockensmithColorado Springs$4K
- Michael RossColorado Springs$4K
- Roger MalloryColorado Springs$4K
- Derian LaiColorado Springs$4K
- Geoffrey BlockLone Tree$726K
- Laura KooiengaDenver$82K
- Brad MarderDenver$77K
- Richard JohnsonAurora$62K
- Maria VelezDenver$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.